A frontline chemotherapy-free strategy using a tyrosine kinase inhibitor and immunotherapy beats the conventional chemotherapy approach for treating Philadelphia-positive acute lymphoblastic leukaemia ...

Brentuximab vedotin (Adcetris, Takeda) is now on the PBS as part of the multi-drug BrECADD chemotherapy regimen for front-line treatment in adult patients with advanced stage CD30+ Hodgkin lymphoma.

JAK inhibitors should be an option for symptomatic myelofibrosis patients even if their disease is low risk, according to new guidelines from the American Society of Hematology (ASH). Published in ...

The addition of the bispecific T-cell engager tarlatamab to durvalumab as first-line maintenance therapy significantly improves survival in patients with extensive-stage small-cell lung cancer (SCLC).